Guggenheim raised the firm’s price target on Tenax Therapeutics (TENX) to $25 from $14 and keeps a Buy rating on the shares. The firm is reiterating Tenax as a Top Pick for 2026 as it nears its first pivotal readout for oral levosimendan in pulmonary hypertension caused by heart failure with preserved ejection fraction in the second half of next year, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX: